Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › Survodutide phase 2 MASH

Survodutide phase 2 MASH

Survodutide · MASH F1–F3

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Survodutide
Population
MASH F1–F3
Official title
A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)
Sponsor
Boehringer Ingelheim
Phase
Phase 2
Registry status
completed · 2021-04 → 2023-11
Participants
295
Duration
48 weeks
Registry
NCT04771273

Outcomes in the indication

Survodutide phase 2 MASH Survodutide · MASH F1–F3 · 48 weeks · n = 293 seed

Histological improvement of MASH 83 % vs 18 %

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Survodutide phase 2 MASH. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/survodutide-phase-2-mash/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.